(Reuters) – British drugmaker GSK on Wednesday beat analyst expectations for its first-quarter profit and sales, ahead of the planned listing of its large consumer healthcare division in July, and stood by its forecasts for 2022.
(Reporting by Pushkala Aripaka in Bengaluru and Natalie Grover in London, Editing by Louise Heavens)
